Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 73 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sicca Syndrome Clear all

Conditions: Graft Vs Host Disease
Interventions: Subconjunctival Cyclosporine Implant; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 9 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dry Eye, Dry Eye, Evaporative, Dry Eye Disease, Evaporative Dry Eye, Evaporative Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions: Miebo; Drug
Lead sponsor: Gordon Schanzlin New Vision; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Keratoconjunctivitis Sicca
Interventions: 1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution; Drug
Lead sponsor: Mimetogen Pharmaceuticals USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Louisville, Kentucky • Nashville, Tennessee

Conditions: Dry Eye Disease, Sjögren Syndrome
Interventions: Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution; Drug
Lead sponsor: Sylentis, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 35 more

Conditions: Keratoconjunctivitis Sicca, Dry Eye
Interventions: rebamipide 2% ophthalmic suspension, placebo eye drops; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 19
States / cities: Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 14 more

Conditions: Keratoconjunctivitis Sicca
Interventions: Lotemax, Restasis, Soothe® Lubricant Eye Drops; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 40 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Irvine, California

Conditions: Keratoconjunctivitis Sicca
Interventions: Hydroeye, Inactive Capsule; Dietary Supplement · Other
Lead sponsor: Virginia Eye Consultants; Other
Eligibility: 40 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 2
States / cities: Houston, Texas • Norfolk, Virginia

Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca, Lacrimal Apparatus Diseases, Keratoconjunctivitis, Eye Diseases, Keratitis, Corneal Disease, Ophthalmic Solution
Interventions: Systane Complete, Systane Ultra; Other
Lead sponsor: Ohio State University; Other
Eligibility: 30 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Keratoconjunctivitis Sicca
Interventions: Not listed
Lead sponsor: TearLab Corporation; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 314 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: San Diego, California • Louisville, Kentucky • Chesterfield, Missouri + 3 more

Conditions: Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions: Oculeve Intranasal, Sham, Oculeve Extranasal; Device
Lead sponsor: Oculeve, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Waterbury, Connecticut • Norfolk, Virginia

Conditions: Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions: Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 19
States / cities: Chandler, Arizona • Sun City, Arizona • Glendale, California + 16 more

Conditions: Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions: Oculeve Intranasal Neurostimulator; Device
Lead sponsor: Oculeve, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Artesia, California • Newport Beach, California

Conditions: Ocular Inflammation, Keratoconjunctivitis, Dry Eye Disease (DED), Post-operative Complications, Kerato Conjunctivitis Sicca, Dry Eye Syndromes, Postoperative Complications
Interventions: Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38%; Drug
Lead sponsor: Harrow Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Keratoconjunctivitis Sicca
Interventions: Rebamipide 1%, Rebamipide 2%, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 63
States / cities: Birmingham, Alabama • Glendale, Arizona • Peoria, Arizona + 55 more

Conditions: Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions: Ophthalmic Emulsion; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more

Conditions: Keratoconjunctivitis Sicca
Interventions: R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 20
States / cities: Artesia, California • Petaluma, California • Rancho Cardova, California + 16 more

Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions: Omega-3 EFA Supplement, Olive Oil; Drug
Lead sponsor: Asbell, Penny, M.D.; Individual
Eligibility: 18 Years to 90 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions: Cyclosporin A; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Keratoconjunctivitis Sicca
Interventions: R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, R348 Ophthalmic Solution, 1.0%, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Dry Eye Disease
Interventions: INV-102, Vehicle; Drug
Lead sponsor: Invirsa, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rush, New York

Conditions: Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema, Corneal Dystrophy, Corneal Ulcer, Foreign Body in Cornea, Bell Palsy, Keratoconjunctivitis, Filamentary Keratitis, Sicca Syndrome; Keratoconjunctivitis (Etiology)
Interventions: Lotrafilcon A contact lenses; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Orlando, Florida • Franklin Park, Illinois • Memphis, Tennessee

Conditions: Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Sacroiliitis, Psoriatic Arthritis, Mixed Connective Tissue Disease, Lupus, Enteropathic Arthropathies, Systemic Sclerosis, Sjogren's Syndrome, Sicca Syndrome, Inflammatory Arthritis, Undifferentiated Connective Tissue Diseases
Interventions: Resource sheets, Community Resource Specialist, Nurse Navigator; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Keratoconjunctivitis Sicca, Dry Eye
Interventions: Tavilermide ophthalmic solution, Placebo; Drug · Other
Lead sponsor: Mimetogen Pharmaceuticals USA, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 19 more

Conditions: Dry Eye
Interventions: Dexamethasone phosphate ophthalmic solution, Sodium citrate buffer solution; Drug
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Waterbury, Connecticut • Lewiston, Maine • Andover, Massachusetts + 2 more

Search by objective public record fields.

Cyclosporine Implant for Ocular Graft-Versus-Host Disease

Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye

Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops

TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease

A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

Tolerability Comparison of Flarex to Lotemax SM

A 1-Year Study in Multiple Clinics Testing Rebamipide Eye Drops for Dry Eye Compared With a Placebo

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

Dry Eye Assessment and Management: Feasibility Study

Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

AONDA Therapeutic Indication Study I

Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity

Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye